2021 – a transformational year for Intravacc
The year 2021 was a transformational year for Intravacc, affecting all levels and departments within the company.
On 1 January 2021, Intravacc became a private entity. We stepped into 2021 as a stand-alone business, transforming from an R&D driven institute towards a full contract development and manufacturing organization (CDMO). As we were all affected by the second year of the COVID-19 pandemic in one way or the other, I am proud and grateful that we still managed to continue our transformation process to ensure our business continuity.
We are delighted with our progress in 2021 and this gives us great confidence to continue to succeed in our mission to become one of the leading CDMO’s within the vaccine and immunotherapy industry and, together with our partners, help to reduce human diseases.